GlassScriptPhysician profile
Robert P Ritchey
NPI 1952388662
$1,578.17
in general payments reported to CMS, 2019-2025
24 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $490 · 2024: $457 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $197.49 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Viiv Healthcare Company | $196.56 | 2024-2025 | Apretude |
| Novo Nordisk INC | $178.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $140.67 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Pfizer INC. | $119.94 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $98.82 | 2023-2024 | Spravato |
| Nevro Corp. | $97.35 | 2023 | Senza |
| Vertex Pharmaceuticals Incorporated | $80.95 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.14 | 2022-2024 | |
| Exact Sciences Corporation | $64.40 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $57.14 | 2024-2025 | Dexcom G6 Transmitter |
| Theratechnologies INC. | $41.03 | 2023 | Trogarzo, Egrifta |
| Astrazeneca Pharmaceuticals LP | $29.49 | 2022-2023 | Breztri |
| Regeneron Healthcare Solutions, INC. | $25.07 | 2024 | Dupixent |
| Sanofi Pasteur INC. | $24.75 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.75 | 2025 | Injectafer |
| Lilly USA, LLC | $19.83 | 2023 | Jardiance, Emgality |
| Novavax INC | $19.48 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Glaxosmithkline, LLC. | $18.39 | 2024 | Shingrix, Arexvy, Bexsero |
| Collegium Pharmaceutical, INC. | $17.99 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $17.95 | 2024 | Auvelity |
| Alk-Abello, INC | $17.72 | 2023 | Grastek, Odactra |
| Mylan Specialty L.P. | $14.22 | 2024 | Yupelri |
| Neurocrine Biosciences, INC. | $13.63 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ritchey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.